Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer

Phase I study approach of priming the immune system with Prostvac vaccination, intensified immunotherapy with Ipilimumab to further enhance the immune response.  This was presented by Hapreet Singh M.D. from the National Cancer Institute.

Genentech video explaining the “Security Checkpoint System” is incorporated in the video presentation above. You can view it separately by clicking on the Video below.


This entry was posted in Ask Dr. Barken, Immune Therapy, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer, Vaccine. Bookmark the permalink.